Emerging Antibody-Based HER2 (ErbB-2/neu) Therapeutics

1 June 2000

journal article
Published by SAGE Publications in Breast Disease

Vol. 11 (1) , 113-124
https://doi.org/10.3233/bd-1999-11110

Abstract

Targeting HER2(ErbB-2/neu) overexpressing tumor cells to selectively deliver anticancer agents and thereby reduce host toxicity represents a rational and emerging strategy for the treatment of breast and other epithelial cancers. The extracellular do

Keywords

ANTIBODY
TREATMENT
ERBB
HER2
2/NEU
EPITHELIAL
TOXICITY
ANTICANCER
OVEREXPRESSING
EXTRACELLULAR

This publication has 0 references indexed in Scilit: